Investor overview

Scandion Oncology was established to address one of the most important problems in modern oncology: the treatment of cancers that have developed resistance to chemotherapy.

What makes Scandion Oncology an attractive company for investors?

  • Limited investment horizon: Clinical Phase II studies will be completed within few years after investment.
  • Potential high return: Detailed analyses from Cortris show that the current market for the chosen indications is more than EUR 4 billion in annual peak sales.
  • Strong assets with patent rights: The patents underlying our two major products in development expire in 2036 and 2037.
  • High unmet medical needs: More than 18 million new cases of cancer every year on a worldwide scale. Half of all patients who receive chemotherapy become resistant.
  • Experienced management team: Our executive team includes a CEO with more than 25 years of biotech and pharma experience and a CSO who has authored more than 70 publications, the majority focusing on translational cancer research, biomarkers and drug resistance.
  • Robust pipeline: Scandion Oncology has two major assets under development, SCO-101 and SCO-201, and more than 800 analogues for the future. The target indications for the analogues are solid tumors.
  • Strong clinical data: Our lead product – SCO-101 – has successfully passed four Phase I trials without showing toxicity.
  • Multiple indications: In addition to our lead product SCO-101 targeting metastatic breast cancer and colorectal cancer, we are simultaneously developing SCO-201, which will target other solid tumors.


Interim reports
Year-end reports
Annual reports

Corporate Governance

General meeting
Articles of Association
Incentive program


Scandion Oncology has a strong patent portfolio lasting until 2037.
We believe our patents are attractive for larger pharmaceutical companies to combine with their existing cancer treatments.

Presentations & media coverage

Share information

Share price
Trading abbreviation
Number of shares

Financial calendar

Co-funded by the Horizon 2020 programme of the European Union
Co-funded by the COSME programme of the European Union